The effect of single dose adjunctive dexamethasone implant on diabetic macular edema in patients on anti-vascular endothelial growth factor treatment: 1 year follow-up from a real-life practice

Basit Öğe Kaydı
dc.authorid0000-0003-0829-3912
dc.authorscopusid50263136900
dc.authorscopusid9733109900
dc.authorwosidHorozoglu, Fatih/AAM-4273-2021
dc.contributor.authorSever, Özkan
dc.contributor.authorHorozoğlu, Fatih
dc.date.accessioned2022-05-11T14:35:47Z
dc.date.available2022-05-11T14:35:47Z
dc.date.issued2019
dc.departmentFakülteler, Tıp Fakültesi, Cerrahi Tıp Bilimleri Bölümü, Göz Hastalıkları Ana Bilim Dalı
dc.description.abstractPurpose. - To evaluate the effect of single-dose intravitreal dexamethasone (Dx) implant as an adjunctive treatment for patients undergoing anti-vascular endothelial growth factor (anti-VEGF) treatment with poor response. Material and methods. - Eighty-four eyes of 72 patients with non-proliferative diabetic retinopathy and diabetic macular edema with a poor response to 3 loading doses of intravitreal ranibizumab (IVR) were included in this study. Group 1 consisted of forty-four eyes which went on a Pro re Nata (PRN) dose regimen of IVR injections after 3 loading doses of ranibizumab, and Group 2 consisted of 40 eyes which received a single dose Dx implant as the 4th injection after 3 loading doses of ranibizumab injections and then went on PRN IVR injections. Patients whose macular edema was unchanged or decreased by < 25% and gained three letters or less on the Early Treatment Diabetic Retinopathy Study visual acuity (VA) chart were defined as poorly responsive. Follow-up time was 12 months. Results. - After the 12-month follow-up, Group 1 gained a median of five letters, and Group 2 gained a median of three letters. After the fourth injection, both groups had statistically significant VA gains at 4, 6, 7, and 12 months when compared with controls (P< .05). Group 2 had a significantly increased VA at 4 and 6 months when compared with controls. However, beginning at 7 months, Group 1 had significantly increased VA when compared with Group 2. At both 4 and 6 months, controls (first 3 months after Dx implantation) in Group 2 had significantly decreased central macular thickness (CMT) when compared with Group 1. However, after 7 months, there was no significant difference between groups with regard to CMT (P> .05). Conclusion. - A single-dose Dx implant after three consecutive IVR injections for poorly responsive diabetic macular edema has limited effect on either VA or CMT. The need for IVR injections did not decrease with a Dx implant. (C) 2019 Elsevier Masson SAS. All rights reserved.
dc.identifier.doi10.1016/j.jfo.2019.04.009
dc.identifier.endpage1000
dc.identifier.issn0181-5512
dc.identifier.issn1773-0597
dc.identifier.issue9en_US
dc.identifier.pmid31196662
dc.identifier.scopus2-s2.0-85066812703
dc.identifier.scopusqualityQ3
dc.identifier.startpage993
dc.identifier.urihttps://doi.org/10.1016/j.jfo.2019.04.009
dc.identifier.urihttps://hdl.handle.net/20.500.11776/8221
dc.identifier.volume42
dc.identifier.wosWOS:000492723100019
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.institutionauthorSever, Özkan
dc.institutionauthorHorozoğlu, Fatih
dc.language.isoen
dc.publisherMasson Editeur
dc.relation.ispartofJournal Francais D Ophtalmologie
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectRanibizumab
dc.subjectDexamethasone implant
dc.subjectDiabetic macular edema
dc.subjectPoor response
dc.subjectIntravitreal Triamcinolone Acetonide
dc.subjectBevacizumab
dc.subjectRanibizumab
dc.subjectTrial
dc.subjectCytokines
dc.subjectTherapy
dc.titleThe effect of single dose adjunctive dexamethasone implant on diabetic macular edema in patients on anti-vascular endothelial growth factor treatment: 1 year follow-up from a real-life practice
dc.title.alternativeEffet d'une administration unique de dexaméthasone (implant) chez des patients diabétiques atteints d'œdème maculaire traités par antifacteur de croissance endothéliale vasculaire : suivi d'un an en pratique réelle]
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
8221.pdf
Boyut:
940.37 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
Tıp Fakültesi Koleksiyonu